Vistagen Therapeutics, Inc. 8-K

What Happened
Vistagen Therapeutics (NASDAQ: VTGN) announced on Form 8-K that it appointed Angel S. Angelov, M.D., MBA as Chief Medical Officer, effective May 18, 2026. Dr. Angelov joins with extensive clinical development and medical affairs experience, most recently serving as Chief Medical Officer at Theranica (Oct 2024–May 2026) and previously holding senior roles at Karuna Therapeutics and Neurocrine Biosciences. A press release announcing the appointment was attached to the filing.

Key Details

• Start date: May 18, 2026. Base salary: $425,000 per year.
• Signing bonus: $50,000 payable in two tranches (50% at hire, 50% at six-month anniversary) subject to continued employment.
• Annual bonus: Eligible for discretionary cash bonus with an initial target of 45% of base salary, based on performance goals set by the board or compensation committee.
• Equity grant: Inducement grant of options to purchase 150,000 shares; 10‑year term; exercise price $0.5955 (closing price on May 18, 2026). Options begin vesting on the one-year anniversary and vest monthly over 36 months (fully vested on the fourth anniversary, subject to continued service).
• Other: The company entered into an indemnification agreement to advance expenses and indemnify Dr. Angelov to the fullest extent permitted under Nevada law.

Why It Matters
This is a material executive change (Item 5.02) that adds a senior clinical leader with neurology/psychiatry drug-development experience, which could affect Vistagen’s clinical strategy and program execution. Compensation and the option grant are standard inducements; the option exercise price reflects the company’s market close on May 18, 2026. Investors should note the timing of vesting and bonus conditions when assessing potential dilution and executive incentives.